This is an unofficial archive of PsychonautWiki as of 2025-08-08T03:33:20Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
1P-ETH-LAD: Difference between revisions
>LockPicker m added publisher translations |
>LockPicker m addded wiki links |
||
| Line 14: | Line 14: | ||
1P-ETH-LAD's structure contains a bicyclic hexahydro indole fused to a bicyclic quinoline group (nor-lysergic acid). 1P-ETH-LAD does not contain a methyl group substituted at R<sub>6</sub> of its nor-lysergic acid skeleton; the nor- prefix represents this. Instead, 1P-ETH-LAD is substituted at R<sub>6</sub> with an ethyl group and at R<sub>1</sub> with a propionyl group. At carbon 8 of the quinoline, an N, N-diethyl carboxamide is bound. | 1P-ETH-LAD's structure contains a bicyclic hexahydro indole fused to a bicyclic quinoline group (nor-lysergic acid). 1P-ETH-LAD does not contain a methyl group substituted at R<sub>6</sub> of its nor-lysergic acid skeleton; the nor- prefix represents this. Instead, 1P-ETH-LAD is substituted at R<sub>6</sub> with an ethyl group and at R<sub>1</sub> with a propionyl group. At carbon 8 of the quinoline, an N, N-diethyl carboxamide is bound. | ||
1P-ETH-LAD is a chiral compound with two stereocenters at R<sub>5</sub> and R<sub>8</sub>. 1P-ETH-LAD, also called (+)-D-1P-ETH-LAD, has an absolute configuration of (5''R'', 8''R''). The three other stereoisomers of 1P-ETH-LAD have not been shown to possess psychoactive properties.<ref>{{cite book|last1=Nichols|first1=David E.|year=2017|chapter=Chemistry and Structure–Activity Relationships of Psychedelics|title=Behavioral Neurobiology of Psychedelic Drugs|pages=1-43|doi=10.1007/7854_2017_475|isbn=978-3-662-55878-2|editor1-last=Halberstadt|editor1-first=Adam L.|editor2-last=Vollenweider|editor2-first= Franz X.|editor3-last=Nichols|editor3-first=David E.}}</ref> | 1P-ETH-LAD is a chiral compound with two stereocenters at R<sub>5</sub> and R<sub>8</sub>. 1P-ETH-LAD, also called (+)-D-1P-ETH-LAD, has an absolute configuration of (5''R'', 8''R''). The three other stereoisomers of 1P-ETH-LAD have not been shown to possess psychoactive properties.<ref>{{cite book|last1=Nichols|first1=David E.|author-link=David E. Nichols|year=2017|chapter=Chemistry and Structure–Activity Relationships of Psychedelics|title=Behavioral Neurobiology of Psychedelic Drugs|pages=1-43|doi=10.1007/7854_2017_475|isbn=978-3-662-55878-2|editor1-last=Halberstadt|editor1-first=Adam L.|editor2-last=Vollenweider|editor2-first=Franz X.|editor3-last=Nichols|editor3-first=David E.|editor3-link=David E. Nichols}}</ref> | ||
==Pharmacology== | ==Pharmacology== | ||
| Line 20: | Line 20: | ||
This compound likely acts as a [[Serotonin#The_5-HT_system|5-HT<sub>2A</sub>]] [[Agonist#Agonists|partial agonist]]. The [[psychedelic]] effects are believed to come from 1P-ETH-LAD's efficacy at the 5-HT<sub>2A</sub> receptors. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive. | This compound likely acts as a [[Serotonin#The_5-HT_system|5-HT<sub>2A</sub>]] [[Agonist#Agonists|partial agonist]]. The [[psychedelic]] effects are believed to come from 1P-ETH-LAD's efficacy at the 5-HT<sub>2A</sub> receptors. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive. | ||
1P-ETH-LAD shares many common traits with its parent compound [[LSD]]; it appears to be roughly equal in potency as well as similar in mechanism although the progression and duration of effects are compressed (while remaining qualitatively less intense and more manageable) due to suspected differences in how it is metabolized. Research has shown formation of [[ETH-LAD]] from 1P-ETH-LAD incubated in human serum, suggesting that it functions as a pro-drug.<ref>{{cite web|last1=Brandt|first1=S. D.|last2=Kavanagh|first2=P. V.|last3=Westphal|first3=F.|last4=Elliott|first4=S. P.|last5=Wallach|first5=J.|last6=Stratford|first6=A.|last7=Nichols|first7=D. E.|last8=Halberstadt|first8=A. L.|year=2017|title=Return of the lysergamides. Part III: Analytical characterization of N<sup>6</sup>‐ethyl‐6‐norlysergic acid diethylamide (ETH‐LAD) and 1‐propionyl ETH‐LAD (1P–ETH‐LAD)|journal=Drug Testing and Analysis|volume=9|issue=10|pages=1641-1649|doi=10.1002/dta.2196|issn=1942-7611}}</ref> | 1P-ETH-LAD shares many common traits with its parent compound [[LSD]]; it appears to be roughly equal in potency as well as similar in mechanism although the progression and duration of effects are compressed (while remaining qualitatively less intense and more manageable) due to suspected differences in how it is metabolized. Research has shown formation of [[ETH-LAD]] from 1P-ETH-LAD incubated in human serum, suggesting that it functions as a pro-drug.<ref>{{cite web|last1=Brandt|first1=S. D.|last2=Kavanagh|first2=P. V.|last3=Westphal|first3=F.|last4=Elliott|first4=S. P.|last5=Wallach|first5=J.|last6=Stratford|first6=A.|last7=Nichols|first7=D. E.|author7-link=David E. Nichols|last8=Halberstadt|first8=A. L.|year=2017|title=Return of the lysergamides. Part III: Analytical characterization of N<sup>6</sup>‐ethyl‐6‐norlysergic acid diethylamide (ETH‐LAD) and 1‐propionyl ETH‐LAD (1P–ETH‐LAD)|journal=Drug Testing and Analysis|volume=9|issue=10|pages=1641-1649|doi=10.1002/dta.2196|issn=1942-7611}}</ref> | ||
==Subjective effects== | ==Subjective effects== | ||